Foghorn Therapeutics Inc Cash Flow Conversion Efficiency
Foghorn Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Foghorn Therapeutics Inc (FHTX) has a cash flow conversion efficiency ratio of 0.233x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-18.90 Million) by net assets ($-81.04 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Foghorn Therapeutics Inc (2018–2025)
Cash flow conversion efficiency of Foghorn Therapeutics Inc from 2018 to 2025. This chart illustrates how Foghorn Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Foghorn Therapeutics Inc (FHTX) share price today for real-time trading data and today's change.
Foghorn Therapeutics Inc Cash Flow Conversion Ratio Explained
Foghorn Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Foghorn Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Foghorn Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Foghorn Therapeutics Inc market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Airtificial Intelligence Structures SA
MC:AI
|
0.028x |
|
PVP Ventures Limited
NSE:PVP
|
-0.055x |
|
Mitrabara Adiperdana PT
JK:MBAP
|
-0.004x |
|
Ally Leasehold Real Estate Investment Trust
BK:ALLY
|
0.051x |
|
Binh Dien Fertilizer JSC
VN:BFC
|
0.226x |
|
Polski Holding Nieruchomości SA
WAR:PHN
|
0.014x |
|
BAOZUN INC. A DL -0001
F:2BZ
|
N/A |
|
Matrimony.Com Limited
NSE:MATRIMONY
|
0.140x |
Annual Cash Flow Conversion Efficiency for Foghorn Therapeutics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Foghorn Therapeutics Inc from 2018 to 2025. Review Foghorn Therapeutics Inc free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-108.50 Million | $-86.10 Million | 0.794x | -64.02% |
| 2024-12-31 | $-45.53 Million | $-100.41 Million | 2.205x | +44.14% |
| 2023-12-31 | $-77.19 Million | $-118.11 Million | 1.530x | -99.91% |
| 2022-12-31 | $112.00K | $193.61 Million | 1728.679x | +333351.39% |
| 2021-12-31 | $96.87 Million | $-50.25 Million | -0.519x | -142.38% |
| 2020-12-31 | $146.19 Million | $-31.29 Million | -0.214x | -140.65% |
| 2019-12-31 | $-88.02 Million | $-46.34 Million | 0.526x | -8.71% |
| 2018-12-31 | $-39.27 Million | $-22.65 Million | 0.577x | -- |
About Foghorn Therapeutics Inc
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mu… Read more